On August 31, 2026, Quantum BioPharma Ltd (ticker: QNTM) remains under scrutiny as investors weigh its valuation amid recent news highlighting Quantum Systems’ U.S. expansion. Despite the promising defense startup narrative, QNTM’s financial metrics tell a different story.

• Quantum BioPharma’s Price-to-Sales (P/S) ratio is an extraordinary ~9263.4x compared to its historical median, signaling the market’s expectation of significant future growth; however, earnings-based valuation metrics like P/E are not applicable due to persistent unprofitability.
• GF Score™ stands at a low 21/100, reflecting challenges in profitability and momentum despite decent financial strength.
• The company’s financial strength ranks 7/10, but insider…